Overview

Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Hydroxocobalamin
Methylene Blue
Vitamin B 12